Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Psyence Biomedical ( (PBM) ) is now available.
Psyence Biomedical Ltd. recently appointed its Chief Financial Officer, Mr. Warwick Corden-Lloyd, to its Board of Directors on October 30, 2025. Additionally, on November 4, 2025, the company amended its Common Stock Purchase Agreement with White Lion Capital LLC, enhancing its financial flexibility. Furthermore, Psyence BioMed announced significant progress in its Phase IIb clinical trial for Adjustment Disorder in palliative care, having dosed multiple patients and expanded its clinical sites in Australia. This advancement underscores the company’s leadership in psychedelic drug development and its commitment to generating high-quality data for future regulatory approvals.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a biopharmaceutical company listed on Nasdaq, specializing in psychedelic-based therapeutics using nature-derived psilocybin and ibogaine. The company focuses on addressing unmet mental health needs, particularly in palliative care, through evidence-based development of safe and effective psychedelic treatments.
Average Trading Volume: 599,356
Technical Sentiment Signal: Sell
Current Market Cap: $4.32M
Learn more about PBM stock on TipRanks’ Stock Analysis page.